Sec. 11102. Medicare part D rebate by manufacturers

2,673 words·~12 min read·/bill/117/hr/5376/eas/section-11102·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Part D of title XVIII of the Social Security Act is amended by inserting after section 1860D–14A ( 42 U.S.C. 1395w–114a ) the following new section: Not later than 9 months after the end of each applicable period (as defined in subsection (g)(7)), subject to paragraph (3), the Secretary shall, for each part D rebatable drug, report to each manufacturer of such part D rebatable drug the following for such period: The amount (if any) of the excess annual manufacturer price increase described in subsection (b)(1)(A)(ii) for each dosage form and strength with respect to such drug and period. The rebate amount specified under subsection

(b)for each dosage form and strength with respect to such drug and period. For each applicable period, the manufacturer of a part D rebatable drug, for each dosage form and strength with respect to such drug, not later than 30 days after the date of receipt from the Secretary of the information described in paragraph

(1)for such period, shall provide to the Secretary a rebate that is equal to the amount specified in subsection

(b)for such dosage form and strength with respect to such drug for such period. The Secretary may, for each rebatable covered part D drug, delay the timeframe for reporting the information and rebate amount described in subparagraphs

(A)and

(B)of such paragraph for the applicable periods beginning October 1, 2022, and October 1, 2023, until not later than December 31, 2025. For purposes of this section, the amount specified in this subsection for a dosage form and strength with respect to a part D rebatable drug and applicable period is, subject to subparagraph (C), paragraph (5)(B), and paragraph (6), the estimated amount equal to the product of— subject to subparagraph

(B)of this paragraph, the total number of units of such dosage form and strength for each rebatable covered part D drug dispensed under this part during the applicable period; and the amount (if any) by which— the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds the inflation-adjusted payment amount determined under paragraph

(3)for such dosage form and strength with respect to such part D rebatable drug for the period. For purposes of subparagraph (A)(i), beginning with plan year 2026, the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 340B of the Public Health Service Act. The Secretary shall reduce or waive the amount under subparagraph

(A)with respect to a part D rebatable drug and an applicable period— in the case of a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 506E of the Federal Food, Drug, and Cosmetic Act at any point during the applicable period; in the case of a generic part D rebatable drug (described in subsection (g)(1)(C)(ii)) or a biosimilar (defined as a biological product licensed under section 351(k) of the Public Health Service Act), when the Secretary determines there is a severe supply chain disruption during the applicable period, such as that caused by a natural disaster or other unique or unexpected event; and in the case of a generic Part D rebatable drug (as so described), if the Secretary determines that without such reduction or waiver, the drug is likely to be described as in shortage on such shortage list during a subsequent applicable period. The annual manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebatable drug and an applicable period, is the sum of the products of— the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of such period; and the ratio of— the total number of units of such dosage form and strength reported under section 1927 with respect to each such calendar quarter of such period; to the total number of units of such dosage form and strength reported under section 1927 with respect to such period, as determined by the Secretary. The inflation-adjusted payment amount determined under this paragraph for a dosage form and strength with respect to a part D rebatable drug for an applicable period, subject to paragraph (5), is— the benchmark period manufacturer price determined under paragraph

(4)for such dosage form and strength with respect to such drug and period; increased by the percentage by which the applicable period CPI–U (as defined in subsection (g)(5)) for the period exceeds the benchmark period CPI–U (as defined in subsection (g)(4)). The benchmark period manufacturer price determined under this paragraph for a dosage form and strength, with respect to a part D rebatable drug and an applicable period, is the sum of the products of— the average manufacturer price (as defined in subsection (g)(6)) of such dosage form and strength, as calculated for a unit of such drug, with respect to each of the calendar quarters of the payment amount benchmark period (as defined in subsection (g)(3)); and the ratio of— the total number of units reported under section 1927 of such dosage form and strength with respect to each such calendar quarter of such payment amount benchmark period; to the total number of units reported under section 1927 of such dosage form and strength with respect to such payment amount benchmark period. In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after October 1, 2021, subparagraphs

(A)and

(B)of paragraph

(4)shall be applied as if the term payment amount benchmark period were defined under subsection (g)(3) as the first calendar year beginning after the day on which the drug was first marketed and subparagraph

(B)of paragraph

(3)shall be applied as if the term benchmark period CPI–U were defined under subsection (g)(4) as if the reference to January 2021 under such subsection were a reference to January of the first year beginning after the date on which the drug was first marketed . In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the rebate amount under paragraph

(1)and the inflation adjusted payment amount under paragraph

(3)with respect to such part D rebatable drug and an applicable period, consistent with the formula applied under subsection (c)(2)(C) of section 1927 for determining a rebate obligation for a rebate period under such section. In this subparagraph, the term line extension means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation. In the case of a part D rebatable drug that is a selected drug (as defined in section 1192(c)) with respect to a price applicability period (as defined in section 1191(b)(2)), in the case such drug is no longer considered to be a selected drug under section 1192(c), for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, subparagraphs

(A)and

(B)of paragraph

(4)shall be applied as if the term payment amount benchmark period were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph

(B)of paragraph

(3)shall be applied as if the term benchmark period CPI–U were defined under subsection (g)(4) as if the reference to January 2021 under such subsection were a reference to January of the last year beginning during such price applicability period with respect to such drug . The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment. Amounts paid as rebates under subsection

(b)shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1841. For purposes of carrying out this section, the Secretary shall use information submitted by— manufacturers under section 1927(b)(3); States under section 1927(b)(2)(A); and PDP sponsors of prescription drug plans and MA organization offering MA–PD plans under this part. If a manufacturer of a part D rebatable drug has failed to comply with the requirement under subsection (a)(2) with respect to such drug for an applicable period, the manufacturer shall be subject to a civil money penalty in an amount equal to 125 percent of the amount specified in subsection

(b)for such drug for such period. The provisions of section 1128A (other than subsections

(a)(with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a). There shall be no administrative or judicial review of any of the following: The determination of units under this section. The determination of whether a drug is a part D rebatable drug under this section. The calculation of the rebate amount under this section. In this section: Except as provided in subparagraph (B), the term part D rebatable drug means, with respect to an applicable period, a drug or biological described in subparagraph

(C)that is a covered part D drug (as such term is defined under section 1860D–2(e)). Such term shall, with respect to an applicable period, not include a drug or biological if the average annual total cost under this part for such period per individual who uses such a drug or biological, as determined by the Secretary, is less than, subject to clause (ii), $100, as determined by the Secretary using the most recent data available or, if data is not available, as estimated by the Secretary. The dollar amount applied under clause (i)— for the applicable period beginning October 1, 2023, shall be the dollar amount specified under such clause for the applicable period beginning October 1, 2022, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with October of 2023; and for a subsequent applicable period, shall be the dollar amount specified in this clause for the previous applicable period, increased by the percentage increase in the consumer price index for all urban consumers (United States city average) for the 12-month period beginning with October of the previous period. Any dollar amount specified under this clause that is not a multiple of $10 shall be rounded to the nearest multiple of $10. A drug or biological described in this subparagraph is a drug or biological that, as of the first day of the applicable period involved, is— a drug approved under a new drug application under section 505(c) of the Federal Food, Drug, and Cosmetic Act; a drug approved under an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, in the case where— the reference listed drug approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act, including any authorized generic drug (as that term is defined in section 505(t)(3) of the Federal Food, Drug, and Cosmetic Act), is not being marketed, as identified in the Food and Drug Administration’s National Drug Code Directory; there is no other drug approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act that is rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of Approved Drug Products with Therapeutic Equivalence Evaluations ) and that is being marketed, as identified in the Food and Drug Administration’s National Drug Code Directory; the manufacturer is not a first applicant during the 180-day exclusivity period , as those terms are defined in section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act; and the manufacturer is not a first approved applicant for a competitive generic therapy, as that term is defined in section 505(j)(5)(B)(v) of the Federal Food, Drug, and Cosmetic Act; or a biological licensed under section 351 of the Public Health Service Act. The term unit means, with respect to a part D rebatable drug, the lowest dispensable amount (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, as reported under section 1927. The term payment amount benchmark period means the period beginning January 1, 2021, and ending in the month immediately prior to October 1, 2021. The term benchmark period CPI–U means the consumer price index for all urban consumers (United States city average) for January 2021. The term applicable period CPI–U means, with respect to an applicable period, the consumer price index for all urban consumers (United States city average) for the first month of such applicable period. The term average manufacturer price has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1927(k)(1), with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1927. The term applicable period means a 12-month period beginning with October 1 of a year (beginning with October 1, 2022). The Secretary shall implement this section for 2022, 2023, and 2024 by program instruction or other forms of program guidance. . Section 1847A(c)(3) of the Social Security Act (42 U.S.C. 1395w–3a(c)(3)), as amended by section 11101(c)(1), is amended by striking subsection

(i)or section 1927 and inserting subsection (i), section 1927, or section 1860D–14B . Section 1927(c)(1)(C)(ii)(I) of the Social Security Act ( 42 U.S.C. 1396r–8(c)(1)(C)(ii)(I) ), as amended by section 11101(c)(2), is amended by striking or section 1847A(i) and inserting , section 1847A(i), or section 1860D–14B . Section 1927(b)(3)(D)(i) of the Social Security Act ( 42 U.S.C. 1396r–8(b)(3)(D)(i) ), as amended by sections 11002(b) and 11101(c)(3), is amended by striking or section 1192(f), including rebates under paragraph

(4)of such section and inserting , section 1192(f), including rebates under paragraph

(4)of such section, or section 1860D–14B . Section 1927(k)(1)(B)(i) of the Social Security Act ( 42 U.S.C. 1396r–8(k)(1)(B)(i) ), as amended by section 11001(b)(3) and section 11101(c)(4), is amended by adding at the end the following new subclause: in subclause (VI), by striking and at the end; in subclause (VII), by striking the period at the end and inserting a semicolon; and by adding at the end the following new subclause: rebates paid by manufacturers under section 1860D–14B. . In addition to amounts otherwise available, there are appropriated to the Centers for Medicare & Medicaid Services, out of any money in the Treasury not otherwise appropriated, $80,000,000 for fiscal year 2022, including $12,500,000 to carry out the provisions of, including the amendments made by, this section in fiscal year 2022, and $7,500,000 to carry out the provisions of, including the amendments made by, this section in each of fiscal years 2023 through 2031, to remain available until expended.

Connections5 off-index

5 references not yet in our index

42 USC 1395w–114a
42 USC 1395w–3a(c)(3)
42 USC 1396r–8(c)(1)(C)(ii)(I)
42 USC 1396r–8(b)(3)(D)(i)
42 USC 1396r–8(k)(1)(B)(i)

Citation graph

cites case law

Sec. 11102

Medicare part D rebate by manufacturers

Cite42 USC 1395w–114a

Cite42 USC 1395w–3a(c)(3)

Cite42 USC 1396r–8(c)(1)(C)(ii)(I)

Cite42 USC 1396r–8(b)(3)(D)(i)

Cite42 USC 1396r–8(k)(1)(B)(i)

Cites 5Cited by 0 across 0 sources